Carrots or Sticks: An Industry Perspective on the Significance of Regulatory Guidance in Promoting Participant Diversity in Clinical Trials

por Peters, Ubong, Spahn, Jessica, Patel, Shilpen
Publicado 2023

Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance

por Wang, Yulei, Lu, Li-Chun, Guan, Yinghui, Ho, Ming-Chih, Lu, Shan, Spahn, Jessica, Hsu, Chih-Hung
Publicado 2021

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

por Kim, Dong-Wan, Gadgeel, Shirish, Gettinger, Scott N., Riely, Gregory J., Oxnard, Geoffrey R., Mekhail, Tarek, Schmid, Peter, Dowlati, Afshin, Heist, Rebecca S., Wozniak, Antoinette J., Singh, Jatinder, Cha, Edward, Spahn, Jessica, Ou, Sai-Hong Ignatius
Publicado 2022

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models

por Spahn, Jessica, Peng, Jing, Lorenzana, Edward, Kan, David, Hunsaker, Thomas, Segal, Ehud, Mautino, Mario, Brincks, Erik, Pirzkall, Andrea, Kelley, Sean, Mahrus, Sami, Liu, Liling, Dale, Stephanie, Quiason, Cristine, Jones, Elizabeth, Liu, Yichin, Latham, Sheerin, Salphati, Laurent, DeMent, Kevin, Merchant, Mark, Hatzivassiliou, Georgia
Publicado 2015